Results 61 to 70 of about 4,782 (272)
Objective This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among rheumatology patients, and their associations with patient factors, patient reported perceived side effects and positive impacts. Methods An online survey (delivered from March to November 2022) was distributed by Alberta Health Services to ...
Susan Zhang +10 more
wiley +1 more source
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease (Review) [PDF]
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropiumare commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease ...
Aaron +32 more
core +1 more source
Inflammation associated with chronic obstructive pulmonary disease (COPD) causes narrowing of the airways and destruction of the lung parenchyma. The triple therapy (ICS+LABA+LAMA) may improve lung function, patient‑reported outcomes, and exacerbation risk in a specified subset of GOLD group D patients.
S, Lassan, J, Keszegh, M, Lassanova
openaire +2 more sources
Biocompatible but Antibacterial Mechanism of Graphene Oxide for Sustainable Antibiotics
Graphene oxide (GO) exhibits selective antibacterial activity through specific interactions between its oxygen functional groups and bacterial membrane phospholipid POPG, causing membrane destabilization while maintaining biocompatibility. Model membrane studies and infected wound models in mice and pigs demonstrate effective bacterial suppression and ...
Sujin Cha +15 more
wiley +1 more source
FULFIL Trial: Once-Daily Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease [PDF]
RATIONALE: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.
Barnacle, H +10 more
core
Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease [PDF]
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease.
Aaron +47 more
core +1 more source
Pressure skin wounds are frequent complications after spinal cord injury (SCI), with impaired healing due to vascular and immune deficits. Elastin‐like polypeptides (ELP) fused to α‐MSH (MSH‐ELP) or MCP‐1 (MCP‐ELP) are developed and tested on these wounds. The resulting nanoparticles are non‐toxic and bioactive, and they enhance macrophage recruitment,
Suneel Kumar +7 more
wiley +1 more source
Kieran J Rothnie,1 Sandra Joksaite,1 Leah B Sansbury,2 Chris Compton,3 Valentina Di Boscio,4 Afisi S Ismaila5,6 1Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK; 2Value Evidence and Outcomes, R&D Global Medical ...
Rothnie KJ +5 more
doaj
Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD.
Fulvio Braido +5 more
doaj +1 more source
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma (Protocol) [PDF]
Background Long-acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD), are being considered as an add-on option for adults with asthma whose condition is uncontrolled on inhaled ...
Adams +14 more
core +2 more sources

